AKSA PHARMA
The computed 12-month bankruptcy probability of AKSA PHARMA is 1.9% (moderate). The 2024 annual accounts show equity of €157k and a net result of €-54k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 66% of 866 sector peers (fiscal year 2024). The company has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €157k |
| Net result | €-54k |
| Staff (FTE) | 3.6 |
| Better than sector | 66% |
Fragile profile, watch profitability in particular.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 29.9% | 17.3% | |
| Net result | €-54k | €14k | |
| Equity | €157k | €100k | |
| Gross operating margin | €174k | €213k | |
| Staff costs | €185k | €219k |
| Fiscal year | 2024 |
|---|---|
| Deposit | volledig |
| Revenue | - |
| EBITDA | €-11k |
| Net profit | €-54k |
| Cash flow | €-25k |
| Staff costs | €185k |
| Income taxes | - |
| Dividends | - |
| Total assets | €524k |
| Equity | €157k |
| Debt | €368k |
| of which ≤ 1y | €368k |
| of which > 1y | - |
| Working capital | €-15k |
| Employees (FTE) | 3.6 |
| 2024 | |
|---|---|
| Current ratio | 0.96 |
| Quick ratio | 0.35 |
| Working capital ratio | -2.9% |
| Solvency | 29.9% |
| Debt / equity | 2.35 |
| Long-term debt ratio | - |
| Interest coverage | -0.83 |
| Gross margin | - |
| Net margin | - |
| ROA | -10.3% |
| ROE | -34.5% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €524k |
| Fixed assets | 21/28 | €172k |
| Intangible fixed assets | 21 | €42k |
| Tangible fixed assets | 22/27 | €112k |
| Financial fixed assets | 28 | €18k |
| Current assets | 29/58 | €352k |
| Stocks & contracts in progress | 3 | €225k |
| Amounts receivable within one year | 40/41 | €123k |
| Cash & bank | 54/58 | €1k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €524k |
| Equity | 10/15 | €157k |
| Contributions / capital | 10/11 | €19k |
| Accumulated profits (losses) | 14 | €138k |
| Amounts payable | 17/49 | €368k |
| Amounts payable within one year | 42/48 | €368k |
| Trade debts payable within one year | 44 | €172k |
| Income statement | ||
| Gross operating margin | 9900 | €174k |
| Operating result | 9901 | €-40k |
| Financial charges | 65 | €14k |
| Result before taxes | 9903 | €-54k |
| Net result for the period | 9904 | €-54k |
| Result to be appropriated | 9905 | €-54k |
-
Current17-11-2023 → present
3 events
- 17-11-2023 Mandate renewed· Director
- 17-11-2023 Resigned· Managing director
- 01-08-2018 Appointed· Managing director
Former directors (1)
-
Former- → 01-08-2018
| NACE primary | Detailhandel in farmaceutische producten(47730) |
| Legal form | Private limited company(610) |
| Incorporation | 11-04-2016 |
| Status | Active |
| Postal code | 1020 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21674C0095/00M007 | Brussels | 5.2 ha | 1 · 1.2 ha | 17.1 m · 3 fl. |
| 21819C0181/00A009 | Brussels | 200 m² | 1 · 89 m² | 13.8 m · 4 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
03-11-2025 Registered office moved
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": null,
"region": null,
"street": "BOULEVARD DE LA WOLUWE",
"country": "BE",
"postcode": null,
"box_number": "14",
"street_number": "70"
},
"old_address": {
"city": "BRUXELLES",
"region": null,
"street": "AVENUE DE L\u0027ARAUCARIA",
"country": "BE",
"postcode": "1020",
"box_number": null,
"street_number": "79"
},
"effective_date": "2025-10-05",
"evidence_quote": "L\u0027assembl\u00E9e propose de transf\u00E9rer le si\u00E8ge social de la soci\u00E9t\u00E9 \u00E0 Avenue de l\u0027Araucaria 79 - 1020 Bruxelles \u00E0 la date du 05 octobre 2025."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0651.787.243",
"name_full": "AKSA PHARMA",
"legal_form": "SRL"
}
}17-11-2023 1 resigning, 1 reappointed
- BONTEMPS Richard, Gedelegeerd bestuurder
- BONTEMPS Richard, Bestuurder
Technical details
{
"events": [
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "BONTEMPS Richard",
"address": null,
"birth_date": null
},
"evidence_quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de mettre fin \u00E0 la fonction du g\u00E9rant actuel mentionn\u00E9 ci-apr\u00E8s, et proc\u00E8de imm\u00E9diatement au renouvellement de sa nomination comme administrateur non statutaire pour une dur\u00E9e illimit\u00E9e : Monsieur BONTEMPS Richard pr\u00E9nomm\u00E9 ici pr\u00E9sent et qui accepte. Son mandat est gratui",
"discharge_granted": false
},
{
"kind": "director_out",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "BONTEMPS Richard",
"address": null,
"birth_date": null
},
"evidence_quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de mettre fin \u00E0 la fonction du g\u00E9rant actuel mentionn\u00E9 ci-apr\u00E8s",
"discharge_granted": false
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0651.787.243",
"name_full": "AKSA PHARMA",
"legal_form": "SPRL"
}
}27-04-2020 Registered office moved from BRUXELLES to Woluwe-Saint-Lambert
- AVENUE ROGIER 315, 1030 BRUXELLES → boulevard de la Woluwe 70, 1200 Woluwe-Saint-Lambert
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "Woluwe-Saint-Lambert",
"region": "Brussels",
"street": "boulevard de la Woluwe",
"country": "BE",
"postcode": "1200",
"box_number": "14",
"street_number": "70"
},
"old_address": {
"city": "BRUXELLES",
"region": "Brussels",
"street": "AVENUE ROGIER",
"country": "BE",
"postcode": "1030",
"box_number": null,
"street_number": "315"
},
"effective_date": "2019-10-10",
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale extraoridnaire du 10 octobre 2019 d\u00E9cide de transf\u00E9rer le siege social de la soci\u00E9t\u00E9, \u00E0 partir de ce jour, \u00E0 l\u0027adresse suivante: boulevard de la Woluwe 70 bo\u00EEte 14-1200 Woluw\u00E9 Sa\u00EDnt Lambert."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0651.787.243",
"name_full": "AKSA PHARMA",
"legal_form": "SPRL"
}
}10-08-2018 1 director appointed, 1 resigning
- Richard BONTEMPS, Gedelegeerd bestuurder
- Khemais Ben Mohamed BEN SASSI, Gedelegeerd bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Khemais Ben Mohamed BEN SASSI",
"address": null,
"birth_date": null
},
"effective_date": "2018-08-01",
"evidence_quote": "D\u0027accepter la d\u00E9m\u00EDssion de sa fonction de g\u00E9rant, Monsieur Khemais Ben Mohamed BEN SASSI domicili\u00E9 \u00E0 9200 Dendermonde, Zandvoorstraat 2 (N.N. 54.10.05.339.36);"
},
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Richard BONTEMPS",
"address": null,
"birth_date": null
},
"effective_date": "2018-08-01",
"evidence_quote": "De nommer Monsieur Richard BONTEMPS, domicili\u00E9 \u00E0 1020 Bruxelles, Avenue des Pagodes 262 (N.N. 86.09.01.229.58) en tant que g\u00E9rant en vue d\u0027exercer lesdites fonctions."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0651.787.243",
"name_full": "AKSA PHARMA",
"legal_form": "SPRL"
}
}13-04-2016 Incorporation of a new SNC
Technical details
{
"kind": "oprichting",
"seat": "1030 Bruxelles, Avenue Rogier 315",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1954-10-05",
"name": "Monsieur BEN SASSI Khema\u00EFs",
"niss": null,
"address": "9200 Dendermonde, Zandvoortstraat 1"
},
"share_class": "ordinary",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 13020,
"holder_person_name": "Monsieur BEN SASSI Khema\u00EFs",
"is_subscriber_only": false,
"n_shares_subscribed": 13020,
"amount_subscribed_eur": 13020,
"is_anonymous_silent_partner": false
},
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1957-08-27",
"name": "Madame SMET Anne-Marie, Irene, Theophiel",
"niss": null,
"address": "9200 Dendermonde, Zandvoortstraat 1"
},
"share_class": "ordinary",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 5580,
"holder_person_name": "Madame SMET Anne-Marie, Irene, Theophiel",
"is_subscriber_only": false,
"n_shares_subscribed": 5580,
"amount_subscribed_eur": 5580,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 18600,
"subject_company": {
"kbo": "0651.787.243",
"name_full": "AKSA PHARMA",
"legal_form": "SNC"
},
"initial_directors": [],
"incorporation_date": "2016-04-06",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | AKSA PHARMA |